| 陈 鹏,李 凯,王长利.埃克替尼治疗晚期非小细胞肺癌近期疗效及不良反应评价[J].肿瘤学杂志,2012,18(12):947-951. |
| 埃克替尼治疗晚期非小细胞肺癌近期疗效及不良反应评价 |
| Short-term Response and Toxicity of Icotinib Hydrochloride in the Treatment for Advanced Non-small Cell Lung Cancer |
| 投稿时间：2012-10-15 |
| DOI： |
|
 |
| 中文关键词: 癌，非小细胞肺 盐酸埃克替尼 靶向治疗 癌胚抗原 |
| 英文关键词:carcinoma,non-small cell lung icotinib hydrochloride target therapy carcinoembryonic antigen(CEA) |
| 基金项目: |
|
| 摘要点击次数: 1738 |
| 全文下载次数: 973 |
| 中文摘要: |
| 摘 要：［目的］ 观察盐酸埃克替尼治疗晚期非小细胞肺癌（NSCLC）的近期疗效及不良反应。［方法］ 67例晚期NSCLC患者，均口服盐酸埃克替尼单药治疗，服用至少1个月后评价疗效及安全性。［结果］ 全组67例患者中CR 1例，PR 25例，SD 16例，PD 25例。总有效率（ORR）38.8%（26/67），疾病控制率（DCR）62.7%(42/67)。其中治疗前CEA>30μg/L组ORR 59.5%（22/37），DCR 73.0%（27/37），而治疗前CEA<30μg/L组ORR 13.3%（4/30），DCR 46.7%（14/30），两组ORR、DCR差异均有统计学意义。男性DCR低于女性，且调整吸烟因素后，性别间DCR的差异同样具有统计学意义。多因素分析提示性别及治疗前CEA是否高于30μg/L为近期疗效的独立预测因素。治疗相关不良反应主要为皮疹26.8%（18/67）和腹泻13.4%（9/67）。 ［结论］ 盐酸埃克替尼单药治疗晚期NSCLC近期疗效肯定，治疗相关的不良反应较轻，耐受性好。女性或治疗前CEA较高的患者疗效更佳。 |
| 英文摘要: |
| Abstract: ［Purpose］ To observe short-term response and toxicity of icotinib hydrochloride in the treatment for advanced non-small cell lung cancer(NSCLC). ［Methods］ Sixty-seven cases with NSCLC treated with icotinib hydrochloride alone taken orally for at least one month were enrolled in the study. Efficacy and toxicity were evaluated. ［Results］ Objective response rate（ORR）was 38.8%(26/67)，and disease control rate（DCR）was 62.7%(42/67) in 67 cases， with complete response(CR)，1 case; partial response(PR)，25 cases; stable disease(SD)， 16 cases; and progressive disease(PD)， 25 cases. ORR and DCR were 59.5 %(22/37) and 73.0%(27/37) respectively in patients with CEA>30μg/L， while those CEA<30μg/L were 13.3%(4/30) and 46.7%(14/30) respectively，with significant difference between the two groups. The DCR of male was lower than that of female， and the DCR between genders showed significant difference after adjusting smoking status. Multivariate analysis showed that gender and CEA(＞30μg/L ) were independent prognostic factors for short-term response. The major toxicities were skin rash(26.8%) and diarrhea(13.4%). ［Conclusion］ Monotherapy with icotinib hydrochloride is effective and tolerable for the patients with advanced NSCLC， especially for female patients or patients with CEA elevation. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |